Baxter International Inc. (NYSE:BAX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

24

Baxter International Inc. (NYSE:BAX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective July17, 2017, Baxter International Inc. (the “Company”) appointed Cathy R. Smith to the Company’s board of directors (the “Board”). Ms.Smith was also appointed to the Board’s Audit Committee.

Ms.Smith will be compensated for service as a director to the Company’s Non-Employee Director Compensation Plan and will be eligible to participate in the Company’s Directors’ Deferred Compensation Plan. In connection with joining the Board, Ms.Smith was granted equity awards as compensation for her 2017 service (representing the period between her appointment date and the Company’s 2018 Annual Meeting of Stockholders) in an amount consistent with the awards granted annually to non-employee directors, prorated for the number of months to be served in accordance with the terms of the Company’s Non-Employee Director Compensation Plan.

On July17, 2017, the Company issued a press release announcing the appointment of Ms.Smith to the Board. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 5.02 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Description of Document

99.1 Press Release of Baxter International Inc. dated July17, 2017


BAXTER INTERNATIONAL INC Exhibit
EX-99.1 2 d423935dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   FOR IMMEDIATE RELEASE Media Contact: Bill Rader,…
To view the full exhibit click here

About Baxter International Inc. (NYSE:BAX)

Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

An ad to help with our costs